HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives $16.88 Average Price Target from Brokerages

Posted by on May 23rd, 2026

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM – Get Free Report) has been given a consensus recommendation of “Hold” by the five analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $16.8750.

A number of brokerages have recently issued reports on HCM. Weiss Ratings downgraded shares of HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 1st. Bank of America lowered their price target on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, March 10th. Finally, Wall Street Zen downgraded shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Saturday, March 7th.

View Our Latest Report on HCM

HUTCHMED Price Performance

NASDAQ HCM opened at $11.99 on Friday. HUTCHMED has a 52 week low of $11.72 and a 52 week high of $19.50. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05. The firm’s 50-day simple moving average is $14.01 and its two-hundred day simple moving average is $14.32.

HUTCHMED (NASDAQ:HCM – Get Free Report) last released its quarterly earnings data on Friday, March 6th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $2.50 by ($2.49). The business had revenue of $135.42 million for the quarter, compared to analyst estimates of $290.50 million. Research analysts predict that HUTCHMED will post 0.41 EPS for the current year.

Institutional Investors Weigh In On HUTCHMED

A number of institutional investors and hedge funds have recently modified their holdings of the company. Ameriprise Financial Inc. lifted its holdings in shares of HUTCHMED by 4.7% in the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after buying an additional 698 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of HUTCHMED by 5.9% in the third quarter. Bank of America Corp DE now owns 21,791 shares of the company’s stock worth $343,000 after buying an additional 1,209 shares in the last quarter. Crossmark Global Holdings Inc. lifted its holdings in shares of HUTCHMED by 3.3% in the fourth quarter. Crossmark Global Holdings Inc. now owns 52,476 shares of the company’s stock worth $700,000 after buying an additional 1,680 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of HUTCHMED by 12.1% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock worth $273,000 after buying an additional 1,873 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of HUTCHMED by 1.2% in the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after buying an additional 3,801 shares in the last quarter. 8.82% of the stock is owned by hedge funds and other institutional investors.

HUTCHMED Company Profile

(Get Free Report)

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.

Read More

Analyst Recommendations for HUTCHMED (NASDAQ:HCM)

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.